TELA Bio, Inc. (NASDAQ: TELA) reported Q3 EPS of ($0.42), $0.02 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $19 million versus the consensus estimate of $18.85 million.

GUIDANCE:

TELA Bio, Inc. sees FY2024 revenue of $74.5-76.5 million, versus the consensus of $74.4 million.

For earnings history and earnings-related data on TELA Bio, Inc. (TELA) click here.